MedTrace Logo

Pragmatic Randomised Trial of the ESC 0/1 Versus 0/3 Hour Troponin Pathway

NCT05322395 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3536

Last updated 2024-03-05

No results posted yet for this study

Summary

The primary objective of this study is to assess the feasibility and impact of implementing the ESC 0-1 hour high sensitive troponin pathway in clinical practice and with specific reference to the 0-3 hour pathway currently in use.

The principal outcome measure will be the safety of the 0-1 hour protocol (which is less established and has limited data on safety when implemented in clinical practice)

Conditions

  • Acute Coronary Syndrome
  • Troponin
  • Chest Pain
  • Point-of-care Systems

Interventions

DIAGNOSTIC_TEST

ESC 0/1 hour troponin pathway

randomisation to 0/1 versus 0/3 hour pathway

Sponsors & Collaborators

  • northwest coast academic science network

    collaborator UNKNOWN

  • Quidel Corporation

    collaborator INDUSTRY

  • Siemens Corporation, Corporate Technology

    collaborator INDUSTRY

  • Abbott Diagnostics Division

    collaborator INDUSTRY

  • Liverpool University Hospitals NHS Foundation Trust

    lead OTHER_GOV

Principal Investigators

  • Heather Rodgers · Liverpool University Hospitals NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-10
Primary Completion
2024-06-01
Completion
2024-11-10

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05322395 on ClinicalTrials.gov